FindTrial
Sign In

Finding out the correlation between infusion-related reactions and blood parameters and demographic factors following the initial Rituximab chemotherapy drug infusion dose.

Prevalence and correlation of infusion-related reactions with haematological and demographic factors following the first dose of Rituximab infusion - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/078777
Enrollment
68
Registered
2024-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C819- Hodgkin lymphoma, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Manipal Acedemy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any malignancy receiving rituximab-based chemotherapy

Exclusion criteria

Exclusion criteria: Benign conditions Non hematological malignancies Prior Rituximab administration

Design outcomes

Primary

MeasureTime frame
Prevalence and types of infusion-related reactions following the first dose of rituximab.Timepoint: one time point—

Secondary

MeasureTime frame
Correlation of infusion-related reactions with total leucocyte counts, other hematological parameters, demographic factors and tumor-related factorsTimepoint: one time point—

Countries

India

Contacts

Public ContactDr Karthik S Udupa

Manipal Acedemy of Higher Education

udupa.karthik@manipal.edu9845317153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026